

Karolinska Development AGM 2019: Information on candidates nominated for election or re-election to the board

Re election

Hans Wigzell

Born 1938. Professor Emeritus of Immunology and MD.

Chairman since 2018. Board member since 2006.

Previous assignments include among other the President of Karolinska Institutet's Nobel Committee, and President of Karolinska Institutet and Director General of Smittskyddsinstitutet.

Other appointments: Chairman of Rhenman & Partner Asset Management AB. Board member of Sarepta Therapeutics Inc. and RaySearch Laboratories AB. Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Academy of Sciences.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 36,491 shares and SEK 39,992 convertible loan.

Tse Ping

Born 1952. Honorary Doctorate, Fil Dr hc.

Vice Chairman and Board member since 2015.

Previous appointments include Member of the Ninth, Tenth, and Eleventh National Committee of the Chinese People's Political Consultative Conference.

Other appointments: Founder and CEO of Sino Biopharmaceutical Limited, Chairman and executive director of Hong Kong listed Lamtex Holdings Ltd, Vice Chairman of Charoen Pokphand Group.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 4,853,141 shares and SEK 272,858,294 in convertible bonds (by related legal person).

Vlad Artamonov

Born 1978. MBA, B.Sc.

Board member since 2012.

Previous appointments include Investment Analyst at Greenlight Capital Inc., position in the Global Merger & Acquisition Group at Merrill Lynch in New York.

Other appointments: Board Member of Redbank Energy Ltd. and of Coastal Capital International Ltd., Managing Partner at Coastal Capital International Ltd.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 3,470,541 shares (by related legal person).

Magnus Persson

Born 1960. MD PhD Assoc Prof. Educated at Karolinska Institutet.

Board member since 2017.

Previous appointments include CEO Karolinska Institutet Holding AB, Managing Partner The Column Group, Partner HealthCap, Clinical Research Physician Sanofi.

Other appointments: Galecto Biotech AS (Chairman), SLS Invest AB (Chairman) Health Innovation Platform AB (Chairman), Cantargia AB (Chairman), Initator Pharma (Chairman), Albumedix AS, Immunicum AB and Medical Prognosis Institute AS.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

Holdings in Karolinska Development: -

Theresa Tse

Born 1992. Bachelor's degree of Science in Economics from the Wharton School of University of Pennsylvania.

Board Member since 2017.

Other appointments: Executive Director, the Chairlady of the Board and the Chairlady of the Executive Board Committee and the Nomination Committee, respectively, of Sino Biopharmaceutical Ltd (listed in Hong Kong).

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 4,853,141 shares and SEK 272,858,294 in convertible bonds (by related legal person).

New election

Viktor Drvota

Born 1965. M.D, Ph.D. Associate Prof. In Cardiology.

CEO in Karolinska Development since June 1, 2017, CIO in Karolinska Development 2016-2017.

Previous appointments include Senior Consultant and Associate Professor in Cardiology at the Karolinska Institutet/hospital, responsibility for Life science at SEB Venture Capital Board member in Arexis AB, SBL Vaccin AB, Nuevolution AS, Index Pharma AB, Scibase AB, Airsonett AB among others.

Other appointments: Board member in Modus Therapeutics Holding AB, Dilafor AB, OssDsign AB, Forendo Pharma Ltd and Umecrine Cognition AB, and deputy board member in Promimic AB.

Not independent of the company and its executive management. Independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 24,000 shares, 1,608 418 warrants